All In Biotech

Drug Trial Radar · NCT06840496

To Investigate the Efficacy of Treatment With Oral NA-921 (Bionetide) Versus Placebo in Females With Rett Syndrome

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Bionetide for the Treatment of Girls and Women With Rett Syndrome

Last checked: Nov 19, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 210 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

210

Planned (sponsor's estimate)

Start

Sep 30, 2026

Primary completion

Sep 30, 2027

Study completion Dec 30, 2027

Sponsor

Lead sponsor
Biomed Industries, Inc.Industry
Sponsor type
Industry
Collaborators
Bioneurals Ltd
First posted
Feb 21, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 5 years, up to 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective • To investigate the efficacy of treatment with oral Bionetide versus placebo in girls and women with Rett syndrome Key Secondary Objective • To investigate the efficacy of treatment with oral Bionetide versus placebo on ability to communicate in girls and women with Rett syndrome

Conditions

  • Rett Syndrome

Interventions

  • BionetideDrug

    Bionetide solution of 20-40 mL based on the subject's weight at Baseline, administered twice daily by mouth or gastrostomy tube (G-tube)

  • PlaceboDrug

    Placebo • Bionetide placebo solution administered based on the subject's weight at Baseline, twice daily for 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rett Syndrome Behavior Questionnaire (RSBQ) Total Score - Change From Baseline to Week 12Time frame: Baseline and Week 12
  2. Clinical Global Impression-Improvement (CGI-I) Score at Week 12Time frame: 12 Weeks Treatment Duration

Locations

18 sites in 2 countries. Site status is shown where the registry gives one.

  • Biomed Testing Facility # BIO-01-85012

    Phoenix, Arizona · Recruiting

  • Biomed Testing Facility # BIO-05-92093

    La Jolla, California · Recruiting

  • Biomed Testing Facility # BIO-04-90095

    Los Angeles, California · Recruiting

  • Biomed Testing Facility # BIO-03-95817

    Sacramento, California · Recruiting

  • Biomed Testing Facility # BIO-02-94104

    San Francisco, California · Recruiting

  • Biomed Testing Facility #BIO-06-80042

    Aurora, Colorado · Recruiting

  • Biomed Testing Facility #BIO-07-33606

    Tampa, Florida · Recruiting

  • Biomed Testing Facility #BIO-08-60612

    Chicago, Illinois · Recruiting

  • Maryland Locations Biomed Testing Facility #BIO-9-21205

    Baltimore, Maryland · Recruiting

  • Biomed Testing Facility #BIO-10-02115

    Boston, Massachusetts · Recruiting

  • Biomed Testing Facility #BIO-13-10467

    The Bronx, New York · Recruiting

  • Biomed Testing Facility #BIO-17-19104

    Philadelphia, Pennsylvania · Recruiting

  • Biomed Testing Facility #BIO-19-77030

    Houston, Texas · Recruiting

  • Biomed Testing Facility #BIO-20-98105

    Seattle, Washington · Recruiting

  • Biomed Research Unit-BIO-23-NSW 2050

    Camperdown, New South Wales, Australia · Recruiting

  • Biomed Research Unit-BIO-24-NSW-4101

    South Brisbane, Queensland, Australia · Recruiting

  • Biomed Research Unit-BIO-21-VIC-3084

    Heidelberg West, Victoria, Australia · Recruiting

  • Biomed Research Unit- BIO-22-VIC 3010

    Parkville, Victoria, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.